OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 - June 2, 2026).

Alexandra Leary, MD, PhD, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), oncologist specialising in gynaecological cancers, Chair of the GINECO group and Lead Investigator of the TEDOVA Phase 2 clinical trial of Tedopi®, will present topline results from the TEDOVA trial evaluating Tedopi® as a maintenance treatment of ovarian cancer.

“The neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial”

• Rapid Oral Abstract
• Session: Gynecologic Cancer – Subtrack: Ovarian Cancer
• Abstract 5510
• Room: E450
• May 30, 2026, 8:06-8:12am CDT (3:06-3:12pm EST)

TEDOVA is a three-arm Phase 2 study evaluating Tedopi® as a maintenance treatment, alone or in combination with anti-PD1 immune checkpoint inhibitor Keytruda® (pembrolizumab), versus best supportive care in 185 patients in platinum-sensitive recurrent ovarian cancer  with controlled disease after platinum-based chemotherapy who have already received both bevacizumab and a PARP (Poly ADP-Ribose Polymerase) inhibitor. The primary endpoint is the Progression Free Survival (PFS) of the maintenance of Tedopi®, with a PD1 inhibitor, after platinum-based chemotherapy in relapsed ovarian cancer.

(NCT04713514).